0: SGLT2 inhibitors such as DN and dipeptidyl peptidase-4 (DPP-4) inhibitors like SN is potentially beneficial in achieving glycemic control without the risk of hypoglycemia or weight gain treatment of type 2 diabetes (Santos et al.,  2017).
1: A recent study suggests that in patients with type 2 diabetes, combination therapy (Ji et al.,  2016) provided additional clinical benefit and is well tolerated.
2: Reductions in HbA1c and body weight with DN were observed in patients receiving SN either alone or in combination with metformin (Gallwitz,  2007; Shimoda et al.,  2013).
